Lilly announced the acquisition of Protomer Technologies for an undisclosed amount, although Lilly said the deal is valued at >$1B, including development and commercial milestones. For context, Protomer (view website) is a private biotech company developing novel drug therapies, including glucose-responsive insulin. Below, FENIX provides thoughts on the acquisition in the context of other glucose-responsive programs like Novo Nordisk’s.